Fluticasone prop HFA 110 MCG 12GM
Ended Awarded
- Contract number
- SPE2DB26FJRVU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,398
Award facts
- Contract value 100% obligated
- $1,398.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,398.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fluticasone Propionate HFA 110 mcg inhalers. This firm fixed-price delivery order, issued on October 24, 2025, with an ultimate completion date of October 27, 2025, was awarded without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to streamline pharmaceutical supply chains across the Department of Defense.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and extensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's Indefinite Delivery Contract under PPV-G GEN V, valued at $499.999 billion with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products supporting military healthcare facilities worldwide. This contract structure enables DMS Pharmaceutical Group to serve as a key regional prime vendor contractor, with the current delivery order for Fluticasone Propionate exemplifying the routine medical supply needs fulfillment that characterizes the broader PPV-G GEN V program.
Quick answers
Who was awarded contract SPE2DB26FJRVU?
SPE2DB26FJRVU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DB26FJRVU worth?
The government has obligated $1,398 on SPE2DB26FJRVU.
Is contract SPE2DB26FJRVU an order under another contract?
Yes. SPE2DB26FJRVU is a delivery order under SPE2DB24D9803, an indefinite delivery contract.
Was contract SPE2DB26FJRVU competed?
The extent of competition for SPE2DB26FJRVU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award